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Abstract
Background: Telomeres are nucleoprotein structures present at the terminal region of the chromosomes.
Mutations in genes coding for proteins involved in telomere maintenance are causative of a number of disorders
known as telomeropathies. The genetic origin of these diseases is heterogeneous and has not been determined for
a significant proportion of patients.
Methods: This article describes the genetic characterization of a cohort of patients. Telomere length was
determined by Southern blot and quantitative PCR. Nucleotide variants were analyzed either by high-resolution
melting analysis and Sanger sequencing of selected exons or by massive sequencing of a panel of genes.
Results: Forty-seven patients with telomere length below the 10% of normal population, affected with three
telomeropathies: dyskeratosis congenita (4), aplastic anemia (22) or pulmonary fibrosis (21) were analyzed. Eighteen
of these patients presented known pathogenic or novel possibly pathogenic variants in the telomere-related genes
TERT, TERC, RTEL1, CTC1 and ACD. In addition, the analyses of a panel of 188 genes related to haematological
disorders indicated that a relevant proportion of the patients (up to 35%) presented rare variants in genes related
to DNA repair or in genes coding for proteins involved in the resolution of complex DNA structures, that participate
in telomere replication. Mutations in some of these genes are causative of several syndromes previously associated
to telomere shortening.
Conclusion: Novel variants in telomere, DNA repair and replication genes are described that might indicate the
contribution of variants in these genes to the development of telomeropathies. Patients carrying variants in
telomere-related genes presented worse evolution after diagnosis than the rest of patients analyzed.
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Background
Chromosome ends are protected by nucleoprotein struc-
tures, the telomeres. In humans, telomere DNA is com-
posed by multiple repetitions of the TTAGGG
hexanucleotide [1]. The 3′ end of telomeres is formed by a
G-rich single stranded extension that invades the upstream
double-stranded region to form telomeric loops (T-,
D-loop). Telomere DNA is bound by a protein complex
named shelterin [2] and this nucleo-protein structure pro-
tects chromosome ends from degradation and is critical for
genome stability (recently reviewed in [3]).
Telomeres cannot be completely synthesized during
DNA replication, which is known as the end-replication
problem and results in progressive shortening of the telo-
meres as cells proliferate. In most organisms, telomere
DNA is elongated after each round of DNA replication by
a specialized complex with reverse transcriptase activity
known as telomerase [4]. The enzymatic activity of the
complex is provided by the TERT (telomerase reverse
transcriptase) protein while the RNA component TR (tel-
omerase RNA, encoded by TERC) is used as template. Es-
sential components of the complex are also DKC
(Dyskeratosis congenita), NOP10, NHP2 and GAR1 pro-
teins, which bind and stabilize TR and are required for tel-
omerase complex assembly [5].
Telomere replication, elongation and protection are
impaired by the strong secondary and tertiary structure
of their DNA [6]. The high content of Guanines of the
telomeres makes them prone to form secondary struc-
tures such as G-quadruplexes. In addition, the T- and
D-loops impair the access of the replicative machinery.
These structures are solved by helicases and structure-
specific endonucleases.
In the absence of a functional telomerase complex,
telomeres are progressively shortened. One of the main
functions of telomere structure is to avoid the recogni-
tion of telomeres as damaged DNA which is achieved by
inhibitory interactions between shelterin components
and DNA-repair proteins [7]. When several telomeres
reach critically short length the structure of the nucleo-
protein complex can no longer be maintained. In that
case, telomeres are recognized as damaged DNA and a
response is triggered that can result in cell-cycle arrest,
cell apoptosis or senescence [8].
The presence of functional mutations in the genes cod-
ing for proteins of the shelterin and telomerase complexes
and auxiliary proteins causes a number of diseases named
telomeropathies or telomere biology disorders that may
affect different organs [9, 10]. Telomeropathies are very
heterogeneous diseases depending on the gene mutated
and the specific mutations, their penetrance and the exist-
ence of anticipation effects. Therefore, patients with the
same mutation can present different manifestations. Some
patients present severe symptoms at an early age such as
those of dyskeratosis congenita (DC) or the related
Hoyeraal-Hreidarsson, Resvesz and Coats plus syndromes
[11]. Other diseases may appear later such as Aplastic
Anemia, (AA) (20–30 years) [12] or pulmonary fibrosis
(40–60 years) (PF) [13]. Mutations in 13 different genes
have been identified as causative of these diseases but a
large number of patients remain genetically undiag-
nosed [14].
Variants in the gene coding for one helicase, RTEL1
(OMIM 608833) are also present in patients with telo-
meropathies [15]. Others helicases and nucleases, like
SLX4, BLM, WRN and RecQL4, have been shown to
participate in telomere preservation [16]. Actually, muta-
tions in some of these genes also result in telomere
shortening [16, 17]. The term secondary telomeropathies
has been recently proposed for diseases caused by muta-
tions in this group of genes [18].
The reduced number of patients of these rare diseases
and the number of putative candidate genes makes
their molecular diagnosis challenging. In this article,
the molecular analysis of 47 patients treated in Spanish
hospitals was performed. Twenty-six of them were di-
agnosed of DC or AA and twenty-one of PF. The re-
sults obtained identified possibly pathogenic variants at
the telomere-associated genes TERT, TERC, ACD,
CTC1 and RTEL1 in heterozygosis. In addition, a sig-
nificant proportion of patients presented rare variants
in genes coding for proteins involved in DNA repair
and in the resolution of complex DNA structures.
Methods
Patients
Patients with severe telomere shortening (percentile < 10)
who presented dyskeratosis congenita (DC), aplastic
anemia (AA) or pulmonary fibrosis (PF) (sporadic and fa-
milial forms) were included. These patients were diag-
nosed, treated and followed in Spanish reference health
care provider centres for these rare diseases. DC was diag-
nosed in patients with the characteristic mucocutaneous
symptoms, nail dystrophy, abnormal skin pigmentation,
oral leukoplakia and bone marrow failure. The diagnosis
of AA was based on bone marrow and blood cells counts.
The diagnosis of PF was established in accordance to
international guidelines [19]. The more relevant character-
istics of the patients are summarized in Additional file 1:
Table S1. All samples were collected after obtaining in-
formed consent for genetic analysis, including for re-
search. Clinical and demographic data were collected.
Genetic analyses
The existence of sequence variants in the TERT, TERC and
DKC1 genes was determined in six patients by PCR ampli-
fication of exons, high resolution melting analyses (HRM)
and sequencing of candidate exons as previously described
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[20]. Later on, genetic analysis of 41 patients was made by
massive parallel sequencing using a panel of genes related
to haematological disorders, as shown in Additional file 1:
Table S2 (MBFSv1.1 panel). Detailed protocols are pre-
sented in Additional file 1: Supplemental Material.
Telomere length determination
Telomere length was determined by two different methods,
Southern blots of enzymatically digested DNA (Additional
file 1: Figure S1) and quantitative PCR. Both methods have
been previously used for determination of telomere length
from patients with inherited bone marrow failure [21]. De-
tailed protocols are presented in Additional file 1: Supple-
mental Material.
Ethical statement
All the participants in this study provided written in-
formed consent for genetic analysis. The investigation
was conducted in accordance with the ethical standards
of the Declaration of Helsinki and the guidelines of the
concerned hospitals.
Results
Single nucleotide variants in genes related to telomere
biology
The possible genetic bases of the diseases were studied
in patients that presented symptoms related to dyskera-
tosis congenita (DC), either mucocutaneous symptoms
or, more often, aplastic anemia (AA) or sporadic or fa-
milial cases of pulmonary fibrosis (PF). Patients with
these diseases present significant telomere shortening.
According to previous reports [12, 22], patients with
telomere length below the 1 % of the age-mated popula-
tion in the case of DC and < 10% in AA and PF where
included in this study. Beside clinical symptoms, DC/AA
and PF patients differed at the age of presentation of the
disease, 12.2 + 12.2 years for DC/AA and 58.3 + 10.2
years for PF (Additional file 1: Table S1).
First analyses were made in six patients by PCR ampli-
fication of exons of the DKC, TERT and TERC genes
using the previously described High-resolution melting
and DNA sequencing method [20] (Patients indicated by
an asterisk in Tables 1, 4 and Additional file 1: Table S1).
Subsequently, taking advantage of newer technologies,
DNA samples of 41 patients were analyzed by massive
sequencing of a panel of genes related to haematological
disorders including all the genes previously associated to
telomere-related diseases (Additional file 1: Table S2).
Out of these patients, 23 were diagnosed of DC/AA and
18 of PF.
Nucleotide variants were further analysed when their
frequency in the general population was lower than one in
a thousand. The results obtained for genes previously re-
lated to telomere shortening are shown in Table 1. These
studies allowed the identification of single nucleotide vari-
ants (SNVs) and indels at TERT, TERC, RTEL1, ACD and
CTC1 genes in heterozygosis. Histograms of the Sanger
sequencing reaction confirming these variants are shown
in Additional file 1: Figure S2.
TERT variants were found in eight patients (Table 1).
AA patient 129 presented two missense variants, p.P65T
and p.C931R. The p.P65T variant was inherited from the
mother of the patient, which also presented short telo-
meres. The p.C931R variant was not present in the parents
of the patient. AA patient 196 presented in heterozygosis a
deletion of two nucleotides at positions c.475_476 that pro-
duced a frame shift mutation after the amino acid residue
158. One stop codon will be found 31 residues down-
stream, resulting in a 189 amino acids-long protein. This
variant was inherited from the father of the patient, which
presented PF. A son of the patient that also presented this
variant, died before birth. AA patient 263 carried in hetero-
zygosis the TERT p.V84E variant. His father also carries the
variant in heterozygosis and presents PF and short telo-
meres. A sister that carries the variants is presently un-
affected at the age of 33 years (Fig. 1).
PF patient F075 presented two missense variants at TERT,
p.R447C and p.R742H. The variant p.R742H has been
already reported [23] while the p.R447C variant is described
for the first time. The mother and a brother of this patient
died of PF. PF patient F185 presented the p.S602 L amino
acid variant. PF patient F219 presented the p.R671W vari-
ant, reported to be pathogenic [24]. PF patient F220 pre-
sented an in-frame deletion at amino acids 671_672 that
has not been previously described. A variant in a splicing
consensus site was found in patient F400.
Variants in TERC were found in three patients (Table 1).
AA patient 156 presented in heterozygosis a deletion of
two bases (r.96_97delCU) that has been previously de-
scribed [25]. The mother of the patient died with PF and
liver cirrhosis, a brother carrying this variant also presented
liver cirrhosis and short telomeres. However, a sister that
carries the variant is presently healthy at the age of 40 years
even if her telomeres are short. PF patient F120 presented
the r.269G >A variant, that has not been previously re-
ported. PF patient F253 presented the undescribed r.23G >
C variant. PF patient F219 presented the p.P722S variant in
CTC1 that has not been previously described.
Four patients presented rare variants in RTEL1 in het-
erozygosis (Table 1). AA patient 90 presented the p.R998*
variant recently reported as pathogenic [26]. The father
and one sister of the patient carried this variant, and pre-
sented short telomeres (Fig. 1). A representative Southern
blot of telomeres including relatives of patient 90 is shown
in Additional file 1: Figure S1. In addition, patient 90 and
mother carried the p.Q929del variant, recently described
[26]. AA patient 211 presented the new pS483I variant
and the described p.C1244R variant [27]. In addition,
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patient 211 presented the amino acid variant p.F818S in
PALB2 protein, also involved in telomere maintenance, as
will be discussed later. The RTEL1 variant p.C1244R was
inherited from the father and the RTEL1 variant p.S483I
and the PALB2 variant from the mother and both parents
presented average telomere length (Fig. 1). PF patient F001
presented the p.R998* pathogenic variant. This RTEL1 vari-
ant was present in the three analyzed relatives of patient
F001, all with short telomeres (Fig. 1). PF patient F020 pre-
sented the described p.F988 L [15] and the non-described
p.R574C variants.
Nucleotide variants in ACD, coding for the TPP1 shel-
terin protein, were observed in two patients. AA patient
145 presented the p.P16Q amino acid variant and AA
patient 109 the p.V94I variant, both in heterozygosis.
The variant of patient 145 is inherited from the mother
that reports several relatives affected of DC. Patients 109
and 145 presented chromosome 7 monosomy.
Single nucleotide variants in genes related to DNA repair
and homologous recombination
Massive sequencing identified a number of rare SNVs (fre-
quency lower than one in a thousand) in genes coding for
proteins involved in DNA repair by homologous recombin-
ation, as shown in Table 2. Among these genes are those
coding for the protein kinases ATM (Ataxia-telangiectasia
mutated) and ATR (Ataxia telangiectasia and Rad3-related),
mutated in the genetic-instability syndromes Ataxia Tel-
angiectasia and Seckel syndrome, respectively. Rare variants
in these proteins were found in 35% of the DC/AA and
17% of the PF patients (Table 2). Fanconi Anemia is also
due to cytogenetic instability, hypersensitivity to DNA
Table 1 Mutations found in telomere-related genes
*Patients analyzed by exon amplification and Sanger sequencing
**The prediction shown is a summary of the ones made by the programs SIFT ensemble 66, Polyphen-2 v2.2.2, MutationAssessor, release 2, FATHMM v2.3, CADD
v1.3 and dbscSNV1.1.
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crosslinking agents and defective DNA repair. This disease
can be caused by mutation in genes that code for compo-
nents of a protein complex involved in DNA repair. Rare
variants in several of these genes (FANCA, FANCD2,
FANCF, FANCL, FANCM, FANCU) were found in 22% of
the DC/AA and PF patients (Table 2). The DNA-
associated proteins BRCA1 and BRCA2 (Breast Cancer 1
and 2) also play an important role in DNA break repair and
recombination in association with PALB2 (Partner and
Localizer of BRCA2). Rare variants in the BRCA1, BRCA2
or PALB2 genes were found in 26% of the DC/AA and 17%
of the PF patients (Table 2). RecQL4 is a DNA helicase
(RecQ-like, type 4) involved in DNA damage repair and
rare variants were found in 17 and 11% of DC/AA and PF
patients, respectively. Variants in the gene coding for the
structure-specific-endonuclease subunit SLX4, involved in
DNA repair and replication, were found in 22% of the DC/
AA and 6% of the PF patients (Table 2). Mutations in SLX4
have been associated with Fanconi Anemia (group P). Fi-
nally, single rare variants were found in other genes
coding for proteins involved in DNA repair such as
WRN, BLM, RAD51, RAD51C and NBN in 9 and
17% of the DC/AA and PF patients, respectively.
The variants found in these genes for each patient
are shown in Table 3. Some of these variants are
Table 2 Frequency of rare variants in genes coding for proteins
involved in DNA-Repair
Dyskeratosis/
Anemia
Pulmonary
Fibrosis
ATM/ATR 8/23 (35%) 3/18 (17%)
BRCA1, BRCA2, PALB2 6/23 (26%) 3/18 (17%)
FANC-A, −D2, −F, −L, −M, −U 5/23 (22%) 4/18 (22%)
RECQL4 4/23 (17%) 2/18 (11%)
SLX4 5/23 (22%) 1/18 (6%)
WRN, BLM, NBN, RAD51, RAD51C 2/23 (9%) 3/18 (17%)
Fig. 1 Familiar inheritance of variants in telomere-related genes in patients with aplastic anemia and pulmonary fibrosis. The family of four affected
patients is represented in panels (a-d). The probands (indicated by arrows) of families (a-c) are affected of aplastic anemia and that of family (d) of
pulmonary fibrosis. The number of the family and the variants analyzed are shown in the upper part of each diagram. In the cases where several variants
were studied, they are shown in the heading in the same relative order and colour as in the diagrams. The presence of the variants is represented as
colour-filled squares or circles and that of the presence of the reference allele as empty figures. The number assigned to each patient or relative is
indicated in the upper, right part of each symbol. The age of each individual, the determined telomere size, in kb, and the corresponding percentage of
the age-matched population are shown under each symbol. Relatives affected by pulmonary fibrosis are indicated in the upper left part of their symbol
(PF). Patient F001 in panel (d) had a deceased identical twin brother as indicated by joining them with a broken line
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Table 3 Variants in DNA repair genes
*The prediction shown is a summary of the ones made by the programs SIFT ensemble 66, Polyphen-2 v2.2.2, Mutation Assessor, release 2, FATHMM v2.3, CADD
v1.3 and dbscSNV1.1.
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described for the first time as indicated (“Not
described” in Table 3).
The variants present in each patient and their clinical
evolution from diagnosis are summarized in Table 4.
Two patients with previously described DKC1 muta-
tions, 26 and 36 [20], are included. This table includes
some variants whose frequency is slightly higher than
one in a thousand (indicated in bold letters). One of
them is a variant in the gene POT1 (pQ301H) present at
a frequency of 0.002 in the ExAC database. The change
is possibly damaging and is present in patient F106. A
second variant in NHP2 (p.R101Q) is present at a fre-
quency of 0.002 at the ExAC database. The change is
possibly damaging, and has been detected in three pa-
tients (F200, F120 and 223). Among the proteins in-
volved in DNA repair, two patients (F20, 109) present
the p.T287A variant at the RAD51C gene (frequency of
0.003 in the ExAC database). Other two patients (26 and
134) present the p.A492D variant at the MRE11A gene
(frequency 0.002 in ExAC).
The possible correlation between the presence of rare
variants in proteins involved in DNA repair or replica-
tion, telomere length and clinical manifestation was in-
vestigated in the family of several patients (Fig. 2). AA
patient 134 carries one variant in the ATR gene not pre-
viously described. The variant is inherited from his
Table 4 Genes coding for proteins involved in telomere
biology and DNA repair in which rare variants were found in
the different patients and clinical evolution
Patient Telomere
biology genes
DNA repair
genes
Clinical
evolution
Pulmonary Fibrosis
F001 RTEL1 BRCA2 Deceased
F010 Stable
F020 RTEL1 FANCM, RAD51C Lung
transplant
F021 FANCM Deceased
F025 Lung
transplant
F044 ATM; RECQL4 Disease
progressing
F075* TERT N.D. Deceased
F106 POT1 BRCA1 Lung
transplant
F120 TERC, NHP2 SLX4 Deceased
F179 BRCA2 Disease
progressing
F185* TERT N.D. Deceased
F188 RECQL4 Disease
progressing
F200 NHP2 ATR Deceased
F213 Disease
progressing
F219 TERT, CTC1, RTEL1 FANCU Deceased
F220 TERT FANCA Lung
transplant
F242 Lung
transplant
F244 ATR Disease
progressing.
F253 TERC, CTC1 RAD51, RAD51C Deceased
F382 NBN Disease
progressing
F400* TERT N.D. Waiting
transplant
Dyskeratosis/
Aplastic anemia
26 DKC1Ref 19 Mre11A Deceased
36 DKC1Ref 19 ATR, BRCA2 Disease
progressing
44 FANCF Stable
47 ATR, FANCD2,
FANCL, RECQL4, SLX4
Recovered
48 WRN, N.D.
52 FANCM, BLM HSC transplant
62 SLX4 HSC transplant
69 ATM Stable
86 RECQL4 Stable
Table 4 Genes coding for proteins involved in telomere
biology and DNA repair in which rare variants were found in
the different patients and clinical evolution (Continued)
Patient Telomere
biology genes
DNA repair
genes
Clinical
evolution
90 RTEL1 BRCA2 HSC transplant
109 ACD SLX4, Rad51C HSC transplant
121 ATM HSC transplant
129* TERT N.D. Deceased
134 ATR, Mre11A Stable
145 ACD BRCA2, SLX4 Deceased
156* TERC N.D. Deceased
169 FANCM Deceased
181 RECQL4 Stable
196* TERT N.D. Deceased
198 ATM, FANCL,
PALB2, RAD50
Disease
progressing
204 ATM, RECQL4 Stable
205 Stable
211 RTEL1 PALB2 HSC transplant
223 NHP2 ATM Stable
263 TERT, RTEL1 BRCA2, SLX4 HSC transplant
282 SLX4 N.D.
N.D. Not determined. Boldface: genes that present variants with a frequency
between 0.001 and 0.003 in the ExAC database.
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mother and grandmother, both relatives have short telo-
meres. The father and maternal grandfather, that do not
carry this variant, present an average telomere size.
AA patient 181 present a variant in RECQL4 not de-
scribed previously. This variant is present in the father
with very short telomeres. The mother does not carry
Fig. 2 Familiar inheritance of variants in genes related to DNA repair and replication in patients with aplastic anemia and pulmonary fibrosis. Schematic
representation of four families of patients (indicated by arrows) affected by aplastic anemia (a-c) or pulmonary fibrosis (d). The number of each family and
the variants studied are shown in the upper part of each panel. The presence of the rare variant is indicated as coloured square or circles and the presence
of the reference variant by open figures. In panels (c and d) where several variants were studied, their relative position in the diagrams and colour are
indicated in the upper part. The number of each family member and its possible pulmonary fibrosis diagnosis (PF) is indicated in the upper part of each
symbol. The age, telomere length (kb) and the corresponding percentage of the age-matched population are indicated in the lower part of each symbol
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this variant and has longer telomeres even that below
the average of the population (10%).
AA patient 198 presents a novel variant in ATM and a
rare variant in RAD50. The ATM variant is inherited
from the mother and the RAD50 p.R850Q variant from
the father (Fig. 2). The father present telomeres of aver-
age size and the mother of size bellow the average. How-
ever, the son presents relatively shorter telomeres than
the parents.
The PF patient F106 carries a rare variant in BRCA1
and a relatively rare variant in POT1 (frequency 0.002).
The patient has four brothers and three have been also di-
agnosed of PF. Two of them carry the same variants in
POT1 and BRCA1 and short telomeres. A sister carries
only the BRCA1 variant and very short telomeres although
is presently asymptomatic. Two of the brothers carry ex-
clusively the POT1 mutation and present longer telomeres
(25–50% of the population) although one of them has de-
veloped pulmonary fibrosis. The patient has a daughter,
which inherited the BRCA1 variant and present very short
telomeres. Two nephews and a niece carry the BRCA1
variant and have short telomeres. One niece inherited the
POT1 change and presents short telomeres.
Discussion
The genetic variants present in patients with symptoms of
DC, AA or PF have been studied in a population of patients
from Spanish hospitals. Heterozygous variants were found
in genes previously related to telomeropathies in 17 pa-
tients, 8 diagnosed of DC/AA and 9 of PF (Table 1). Two
variants in ACD were found in the only two AA patients
that also presented chromosome 7 monosomy, previously
associated to the presence of short telomeres in AA pa-
tients as a consequence of chromosomal instability [28].
Several of the variants found had been reported previ-
ously as pathogenic. The TERT variants p.R671W and
p.R742H have been described associated to PF [23, 24].
The TERC variant r.96_97delCU was described in a DC
patient transmitted with a dominant pattern of inheritance
[25]. The RTEL1 variants p.Q929del [26] pF988 L [29],
p.R998* [26] and p.C1244R [27] were described in DC pa-
tients. The RTEL1 p.R574C variant has been described as
a clinical variant. The other variants found in this study
have not been previously reported and according to the
actual guidelines should be considered as variants of un-
known significance (VUS). However, we speculate that
some of them could be pathogenic because they are
closely related to described pathogenic variants, as sche-
matically shown in Fig. 3. This is the case of TERT p.P65T
variants since the p.P65A variant has been found in pa-
tients of acute myeloblastic leukemia (AML) [26]. The
TERT p.V84E variant is close to the p.R83P variant, found
in patients with AA and myelodisplastic syndrome [30]. In
addition, the V84 residue is conserved through evolution
and the V > E change is considered as damaging. Other
variants produced changes potentially damaging in con-
served residues located in functional domains of the pro-
teins like the TERT variants p.F159fsX32 and p.S602 L
that affect residues located in the conserved N-terminal
domain (Fig. 3). The p.F159fsX32 variant would produce a
truncated protein and a situation of functional hemizygo-
sis. The variants p.R672del and pC931R are located in the
reverse transcriptase and C-terminal domains of TERT, re-
spectively (Fig. 3). In the case of the RTEL1 gene, the
pS483I variant in a conserved residue is close to the
p.P484L variant associated to PF [31].
The gene panel used for the analyses of the DNA of
41 patients by massive sequencing detected the presence
of numerous variants in genes coding for proteins
Fig. 3 Schematic representation of the location of TERT variants on the conserved and functional domains of the protein. Conserved regions of TERT are
represented as filled boxes and coloured according to their participation in the protein functional domains (shown in the lower part of the scheme).
Regions of the N-terminal extension, involved in RNA binding, are coloured in blue. Regions of the reverse transcriptase domain (RT-domain) are shown in
cyan and those of the C-terminal extension in green. The location of the new amino acid variants described in the article is shown in the upper part of the
figure. Two previously described variants close to new variants (P65A and R83P) are shown in the lower part of the figure. The location of two variants
found in this project and previously described as pathogenic are shown in the lower part inside boxes
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involved in DNA repair such as ATM, ATR, BRCA1,
BRCA2 and several genes of the FANC complex, mu-
tated in Fanconi Anemia. Variants in genes coding for
DNA helicases and nucleases involved in the resolution
of DNA complex structures, such as SLX4, RECQL4,
WRN, BLM, RAD51, RAD51C or NBN were also found.
Variants in these genes have not been related to telo-
meropathies previously, with the exception of SLX4 [32].
The proteins ATM and ATR play a signalling role in
DNA double-strand break repair pathways and their
continued activation can result in cell cycle arrest, repli-
cative senescence or apoptotic cell death. However, spe-
cific interactions with shelterin protein, ATM/TRF2, and
ATR/TRF1, inhibit their activation to preserve telomere
structure. Therefore, it is conceivable that functional
variants at ATM and ATR could affect telomere struc-
ture and stability. Indeed, cells of Ataxia telangiectasia
patients with homozygous mutations in ATM present
telomere shortening and increase frequency of chromo-
some end-to-end fusions (CEFs) [33].
BRCA1 and BRCA2 proteins also participate in DNA
damage repair by homologous recombination and non-
homologous end joining [34] and play a protective role at
telomeres [35]. BRCA1/2 mutations result in shortening
of the telomere single-stranded overhang and increase
telomere length variability [36]. BRCA2 heterozygous cell
lines present frequently CEFs [37]. Germline mutations in
BRCA1 and BRCA2 are associated with greatly increased
frequency of breast and ovarian cancers and telomere
shortening was associated with genetic anticipation in her-
editary breast cancer [38].
Proteins mutated in Fanconi Anemia (FA) patients are in-
volved in repair of DNA-inter-strand crosslinks and have
been also involved in telomere maintenance (reviewed by
Sarkar and Liu [39]). FA patients are reported to present in-
creased CEFs and overall shorter telomeres [40, 41].
Replication of telomeric DNA presents specific challenges
due to structure of the DNA with unconventional regions
including T loop and G quadruplexes and requires the par-
ticipation of a large number of proteins (reviewed by Marti-
nez and Blasco [6]). Among them are proteins with DNA
helicase activity, like RTEL1, BLM, WRN or RecQL4, endo-
nuclease complexes, like the one formed by SLX4, SLX1,
MU881 and XPF and recombinases like Rad51 and Rad51C.
Mutations in these genes cause diseases with some symp-
toms resembling those of telomeopathies, as mentioned in
the Background section. Many of these diseases show telo-
mere fragility [42], telomere loss and/or increased CEFs
[43]. These proteins are located to telomeres through inter-
actions with TRF1 of TRF2 shelterin proteins [44–48] . In
addition, TERT expression in cells isolated from patients of
these diseases rescue some of their alterations [49, 50]. Var-
iants in SLX4 have been found with increased frequency in
AA patients [32].
The existence of overlapping symptoms in diseases
caused by mutations in genes coding for proteins involved
in telomere-maintenance and in DNA-repair and replica-
tion proteins have been recently reviewed [18]. In this art-
icle we describe the presence of rare variants in many of
these genes in patients that present short telomeres and
telomeropathies such as DC, AA and PF. We consider the
possibility that the presence of one or more variants in
these genes in heterozygosis, some times in addition to
variants in telomere maintenance genes, could have a cu-
mulative pathogenic effect. This association could be ex-
tensive to some more frequent variants in genes involved
in primary telomeropathies, as those observed in NHP2 or
POT1. This possible pathogenic association need to be
confirmed by functional studies and analyzing more ex-
tensive cohorts of patients.
The small number of patients analyzed prevents a stat-
istical analysis of the possible genotype-phenotype cor-
relation. There seems to be, however poor outcome in
patients that carry variants in genes related to telomere
biology, as shown in Table 4. For example, nine AA pa-
tients carried variants in telomere genes and five of them
died in the course of the study and the other four re-
quired hematopoietic stem cell transplantation (HSCT).
In contrast, only one patient died and three required
HSCT of the sixteen that presented short telomeres but
not rare variants in telomere related genes. Similar evo-
lution was observed in PF patients. Nine carried muta-
tions in telomere genes and four died and four required
lung transplant. Of the 12 patients without mutations in
these genes, two died and three required lung transplant.
In particular, the two patients that carried two TERT var-
iants evolved very quickly and both died in a few months
after the diagnosis of the disease. One of these patients
was diagnosed of AA and the other of PF. Among the
patients with worst evolution without mutations in tel-
omerase genes, three presented variants in FANCM (two
died and one required HSCT). However, the analysis of
a larger cohort of patients will be required to confirm or
discard these proposals.
Conclusions
Using massive sequencing of a panel of genes and
Sanger sequencing of selected exons we identified novel
variants in telomere biology genes in a series of patients
of DC, AA and PF form Spanish hospitals. In additions
we describe the existence of frequent rare variants in
genes involved in DNA damage response and the reso-
lution of complex DNA structures in this population of
patients. Achieving a molecular diagnosis from patients
of these telomere biology diseases would be important
for accurate genetic counselling and effective treatment
of the patients.
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